$BOLT News

Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22

HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate

Bolt Metals Corp. Announces Appointment of Chief Financial Officer and Corporate Secretary

HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate

Bolt Biotherapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS (FOR THE TREATMENT OF CANCER)".

Bolt Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Bolt Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Q3 EPS $(3.72) Beats $(5.53) Estimate, Sales $2.169M Beat $725.000K Estimate

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

HC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics Says Initial Phase 1 BDC-4182 Dose Escalation Data Now Expected In Q3 2026, Implements 50% Workforce Cut

Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Q2 EPS $(4.46) Beats $(6.27) Estimate, Sales $1.80M Beat $819.75K Estimate